Germany-based molecular diagnostics company Curetis expanded its series A round on Wednesday to €34m ($48.3m). The additional investment of €9.6m was provided by Roche Venture Fund, the corporate venturing unit of Swiss pharmaceutical company Roche, and venture capital (VC) firms Forbion Capital Partners and CD-Venture.
Other investors in Curetis’ series A round prior to this week are CD-Venture, German government-owned development bank KfW Bankengruppe, private equity funds Aeris Capital and Life Sciences Partners, and VC firm BioMed Partners. Altogether, Curetis…